Cytotoxic and antitumor activity of 1-nitroacridines as an aftereffect of their interstrand DNA cross-linking

Cancer Res. 1984 Oct;44(10):4289-96.

Abstract

To determine whether the toxic effects and changes in many cell functions caused by antitumor 1-nitroacridines are related to their enzymatically mediated covalent interstrand DNA cross-linking (J. Konopa, J. W. Pawlak, and K. Pawlak. Chem.-Biol. Interact., 43: 175-197, 1983), the cross-linking potency of the derivatives with structural modifications in position 9 of the acridine nucleus was estimated as their in vitro threshold concentrations (0.3 to 4.5 microM), beyond which the first interstrand DNA cross-links could be detected in DNA of cultured HeLa S3 cells with a polyethylene glycol 6000-Dextran T500 assay. Statistically significant (p less than 0.05) correlations exist between the cross-linking potency of 1-nitroacridines and their in vivo antitumor activity and toxicity against mice with Sarcoma 180 tumors in solid form (3 to 1065 mumol/kg of body weight), as well as their in vitro cytotoxicity against cultured HeLa or HeLa S3 cells (0.0005 to 7.2 microM), indicating that the interstrand DNA cross-linking potency might be one of primary determinants of in vivo and in vitro biological activity of 1-nitroacridine antineoplastic drugs. Susceptibility of the parent agents to reduction does not appear to be a rate-limiting factor of DNA cross-linking potency of 1-nitroacridines and their metabolic transformations (J. W. Pawlak, and J. Konopa. Biochem. Pharmacol., 28: 3391-3402, 1979), because no significant differences were observed among the agents with respect to their polarographic half-wave potentials estimated under anaerobic conditions.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acridines / therapeutic use
  • Acridines / toxicity*
  • Animals
  • Antineoplastic Agents / toxicity*
  • Cell Survival / drug effects
  • Chemical Phenomena
  • Chemistry
  • DNA, Neoplasm / metabolism*
  • Drug Evaluation, Preclinical
  • HeLa Cells / cytology
  • HeLa Cells / drug effects
  • Humans
  • Mice
  • Nitro Compounds / therapeutic use
  • Nitro Compounds / toxicity
  • Oxidation-Reduction
  • Sarcoma 180 / drug therapy
  • Structure-Activity Relationship

Substances

  • Acridines
  • Antineoplastic Agents
  • DNA, Neoplasm
  • Nitro Compounds